The treatment of metabolic dysfunction-associated steatohepatitis (MASH) has proven challenging, with many compounds failing during development for various reasons. However, with the recent ...

Upstream asserts that verekitug could offer advantages over Tezpire, including potentially greater potency and longer dosing intervals. The company is testing intervals of 12 and 24 weeks in its ...

Cambridge’s Camp4 Therapeutics Inc. and Waltham’s Upstream Bio Inc. will both make their debuts on the public markets Friday.

The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer this year, the most since 2021.

Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populationsSTRO-004 (tissue ...

The Basel, Switzerland-based company said the assay could identify patients with gastric and gastroesophageal junction cancer ...

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial ...

DAYLIGHT ( NCT05033886) is a Phase 3b, randomized, double-blind, placebo-controlled, 24-week study to assess the efficacy and safety of fezolinetant in menopausal women aged 40-65 suffering from ...

Some six years after picking up Seattle’s Universal Cells for $102 million, Astellas Pharma is opening a second location for ...

AlphaFold’s developers were awarded science’s top prize. Elsewhere, J&J is shuttering an intriguing cancer study and Alnylam is asking for approval of a drug that could rival a Pfizer blockbuster.